Therefore, understanding the mechanisms underlying HER2-targeted therapies aligned with the understanding of the molecular and cellular pathways involved in HER2-low breast cancer heterogeneity, is essential for the development of novel therapeutic strategies targeting HER2 and HR to delay disease progression. This evidence concerns the gene ERBB2 and breast cancer.